About this trial

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.

Eligibility criteria

Qualifiers

Female

Age ≥ 18 years at the time of consent.

Stage I-III Breast Cancer

Recommended chemotherapy

Disqualifiers

Allergy to memantine

Previous chemotherapy (prior to the current regimen),

Severe cognitive impairment, defined by Blessed Orientation Memory Concentration Test Score ≥11

Myocardial infarction in the last 6 months

Trial design

Treatments tested in this trial

  • Memantine
  • Placebo medication
  • Exercise Intervention
  • Exercise Control

Treatment groups

90 Participants
are divided into 3 treatment groups

Locations

1
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill27599, Chapel HillNorth Carolina, United States

Sponsors and collaborators

UNC Lineberger Comprehensive Cancer Center

Lead sponsor

National Institute on Aging (NIA)

Collaborator